IGF‐1 as screening tool for acromegaly and adult‐onset growth hormone deficiency in the Netherlands
Clinical Endocrinology, Volume 100, Issue 3, Page 260-268, March 2024.Abstract Objective Insulin‐like growth factor 1 (IGF‐1) measurements play a central role in the diagnosis and follow‐up of acromegaly and growth hormone deficiency. However, improving health care outcomes for these patients involves an intricate process of laboratory diagnostics and skilled health care professionals.
Mark R. Postma +4 more
wiley +1 more source
Prevención del cáncer mediante el control del factor de crecimiento insulínico tipo I. [PDF]
, 2016 Para prevenir el cáncer de forma eficaz es importante conocer cómo se origina y cómo se desarrolla la enfermedad. Evidencias recientes indican que este proceso se origina en las células madre y que el principal motivo biológico del cáncer es la ...
Medina Guerrero, Ana
core
Serum N-Terminal Type III Procollagen Propeptide: An Indicator of Growth Hormone Excess and Response to Treatment in Feline Hypersomatotropism [PDF]
, 2016 BACKGROUND: N‐terminal type III procollagen propeptide (PIIINP) is a biomarker of soft tissue proliferation. Hypersomatotropism (HS) is associated with soft tissue proliferation.
Church, D B +4 more
core +3 more sources
International Journal of Endocrinology, Volume 2024, Issue 1, 2024.The majority of acromegaly and gigantism are caused by growth hormone‐secreting pituitary neuroendocrine tumors (PitNETs). Most cases can be cured or controlled by surgery, medical therapy, and/or radiotherapy. However, a few of these tumors are resistant to traditional therapy and always have a poor prognosis.
Xiaojuan Zhang +4 more
wiley +1 more source
The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets [PDF]
, 2014 Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. Different signalling pathways have been identified to be implicated in the pathogenesis of HCC; among these, GH, IGF and somatostatin (SST) pathways have emerged as some of the
Annamaria Colao +7 more
core +1 more source
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study [PDF]
, 2020 Emmanuelle Kuhn +12 more
openalex +1 more source
Tratamiento médico de tumores hipofisarios
Revista Médica Clínica Las Condes, 2013 Se presentan los diferentes tipos de tumores hipofisiarios y para cada uno las opciones de tratamiento médico disponibles actualmente. Se detallan sus indicaciones, los resultados que se estima posibles, sus efectos secundarios y contraindicaciones.
Dr. C. Pedro Becker
doaj +1 more source
Expression of a glycosylphosphatidylinositol-anchored ligand, growth hormone, blocks receptor signalling [PDF]
, 2012 We have investigated the interaction between GH (growth hormone) and GHR (GH receptor). We previously demonstrated that a truncated GHR that possesses a transmembrane domain but no cytoplasmic domain blocks receptor signalling.
Aiden H. Riley +29 more
core +3 more sources
Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess [PDF]
, 2017 The interplay between vitamin D and the growth hormone (GH)/insulin-like growth factor (IGF)-I system is very complex and to date it is not fully understood.
Ciresi, A., Giordano, C.
core +1 more source
International Journal of Endocrinology, 2012 This paper outlines the present status of medical therapy of acromegaly. Indications for permanent postoperative treatment, postirradiation treamtent to bridge the interval until remission as well as primary medical therapy are elaborated.
U. Plöckinger
doaj +1 more source